ScoreWhy is Jafron Biomedical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 2.86% and Operating profit at -5.91% over the last 5 years
2
With a fall in Net Sales of -39.78%, the company declared Very Negative results in Sep 25
- The company has declared negative results in Mar 25 after 4 consecutive negative quarters
- PRE-TAX PROFIT(Q) At CNY 80.78 MM has Fallen at -73.06%
- NET PROFIT(Q) At CNY 56.94 MM has Fallen at -76.62%
- OPERATING CASH FLOW(Y) Lowest at CNY 779.01 MM
3
With ROE of 20.51%, it has a expensive valuation with a 5.63 Price to Book Value
- Over the past year, while the stock has generated a return of -32.83%, its profits have fallen by -8.8%
- At the current price, the company has a high dividend yield of 3.7
4
Below par performance in long term as well as near term
- Along with generating -32.83% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jafron Biomedical Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jafron Biomedical Co., Ltd.
-33.22%
-1.33
26.76%
China Shanghai Composite
15.17%
1.02
14.86%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
2.86%
EBIT Growth (5y)
-5.91%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.46
Tax Ratio
19.47%
Dividend Payout Ratio
74.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
47.77%
ROE (avg)
24.21%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
5.63
EV to EBIT
20.74
EV to EBITDA
17.56
EV to Capital Employed
6.84
EV to Sales
7.43
PEG Ratio
NA
Dividend Yield
3.68%
ROCE (Latest)
33.00%
ROE (Latest)
20.51%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-28What is not working for the Company
PRE-TAX PROFIT(Q)
At CNY 80.78 MM has Fallen at -73.06%
NET PROFIT(Q)
At CNY 56.94 MM has Fallen at -76.62%
OPERATING CASH FLOW(Y)
Lowest at CNY 779.01 MM
NET SALES(Q)
Lowest at CNY 421.61 MM
Here's what is not working for Jafron Biomedical Co., Ltd.
Net Sales
At CNY 421.61 MM has Fallen at -39.78%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 80.78 MM has Fallen at -73.06%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 56.94 MM has Fallen at -76.62%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Operating Cash Flow
Lowest at CNY 779.01 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Net Sales
Lowest at CNY 421.61 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
